kotak-logo
Corona Remedies  Share Price

Corona Remedies Share Price

1600.7
-15.80 (-0.98%)
CORONA • 12 Mar, 2026 | 12:29 PM
Buywith MTF at 2.50x leverage

Corona Remedies Stock Performance

1W Return2.28
1Y Return0.00
Today's Low1582.3
Prev. Close1,616.50
Mkt Cap (Cr.)9,886.53
1M Return-0.83
3Y Return0.00
52-Week High1699
Open1,610.00
PE Ratio57.53
6M Return0.00
Today's High1621.8
52-Week Low1336.6
Face Value10

Corona Remedies Company background

Founded in: 2004
Managing director: NIRAVKUMAR KIRTIKUMAR MEHTA
Corona Remedies Limited was originally incorporated as CORONA Remedies Private Limited, a private limited company, dated August 27, 2004, issued by the Assistant Registrar of Companies, Gujarat at Dadra and Nagar Haveli. Thereafter, Company converted into a public limited and Company name has changed to CORONA Remedies Limited. A fresh certificate of incorporation, is issued by the Registrar of Companies, Central Processing Centre, Manesar, Haryana on December 16, 2024.The manufacturing facilities of the Company are located at Solan (Himachal Pradesh) and at Bhayla (Ahmedabad, Gujarat). The Company is engaged in manufacturing, trading and marketing of Pharmaceutical products in womens healthcare, cardiodiabeto, pain management, urology and other therapeutic areas. In 2004, Company launched the first division, and later named it as Pioneer division in year 2010 launched Xemx (multispeciality) division in 2005. The production of first manufacturing plant was commissioned at Solan, Himachal Pradesh in 2007. The Company launched Gynaecology division in 2008 further launched Cardioloy division in 2013 launched Cardiovascular disease (CVD) and Solis division in 2016. Later, the production at Ahmedabad Plant commissioned in Gujarat in 2021. Radiance and Solaris Divisions launched in 2022 followed by Urology division in 2023. The Company acquired the Myoril brand from Sanofi Healthcare India Private Limited in strengthening the pain management portfolio in 2024. Company issued 6,174,051 equity shares of face value of Rs 10, by raising Rs 655.37 crore through offer for sale on December 10, 2025. In addition to urology, Company focus on marketing to infertility specialists, IVFfocused chain hospitals and increased medical representative coverage to grow the market share within the therapeutic area.

Corona Remedies Financial Highlights


For the full year FY2025–2026, revenue reached ₹1202.35 crore and profit touched at ₹149.05 crore. As of Dec '25, Corona Remedies’s market capitalisation stood at ₹9,886.53 crores. Shareholding as of Dec '25 shows promoters holding 69%, with FIIs at 1.8%, DIIs at 6.8%, and public at 22.4%.

Corona Remedies Share Price Today


As of 12 Mar 2026, Corona Remedies share price is ₹1600.7. The stock opened at ₹1610 and had closed at ₹1616.5 the previous day. During today’s trading session, Corona Remedies share price moved between ₹1,582.30 and ₹1,621.80, with an average price for the day of ₹1602.05. Over the last 52 weeks, the stock has recorded a low of ₹1,336.60 and a high of ₹1,699.00. In terms of performance, Corona Remedies share price has increased by 50.7% over the past six months and has increased by 13.43% over the last year.
Read More
View details of Market Depth

Corona Remedies Fundamental

Market Cap (in crs)

9,886.53

Face Value

10

Turnover (in lacs)

57.90

Key Metrics

Qtr Change %
50.7
Dividend yield 1yr %
0

Corona Remedies Key Financials

View more
Loading chart...
Corona Remedies Quarterly Revenue
Corona Remedies Yearly Revenue
Corona Remedies Quarterly Net Profit/Loss
Corona Remedies Yearly Net Profit/Loss

Corona Remedies Result Highlights

  • Corona Remedies Ltd reported a 5.2% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Dec (Q3 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a - of -.

  • Its expenses for the quarter were down by 8.0% QoQ and - - YoY.

  • The net profit decreased 21.1% QoQ and - - YoY.

  • The earnings per share (EPS) of Corona Remedies Ltd stood at 6.75 during Q3 FY 2025-26.

    Read more

Data Source: BSE, Company announcements

The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results.

Corona Remedies Technical Analysis

Moving Averages Analysis
1600.7
Current Price
Bullish Moving Averages
11
Bearish Moving Averages
0
Day EMA5
1,600.20
Day EMA10
1,590.50
Day EMA12
1,587.70
Day EMA20
1,574.60
Day EMA26
1,563.00
Day EMA50
1,509.10
EMA
EMA
Delivery & Volume
Loading chart...

Day

33.00%

Week

35.40%

Month

41.80%

Delivery & Volume

1,634.17
Pivot
Resistance
First Resistance
1,667.33
Second Resistance
1,718.17
Third Resistance
1,751.33
Support
First Support
1,583.33
Second support
1,550.17
Third Support
1,499.33
Relative Strength Index
57.79
Money Flow Index
72.16
MACD
24.72
MACD Signal
27.04
Average True Range
61.71
Average Directional Index
17.79
Rate of Change (21)
-1.16
Rate of Change (125)
0.00
Compare

Corona Remedies Shareholding Pattern

Promoter
69%
Foreign Institutions
1.8%
Mutual Funds
6.4%
Domestic Institutions
6.8%
Public
22.4%

Corona Remedies Latest News

07 MAR 2026 | Saturday
27 FEB 2026 | Friday
17 FEB 2026 | Tuesday

Please be aware that Corona Remedies stock prices are subject to continuous fluctuations due to various factors.